Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AMP-201
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : NIH-NIAMS
Deal Size : Undisclosed
Deal Type : Funding
Details : The grant will provide substantial funding for the advancement of AMP-201, an AAV-ColQ gene therapy designed to address the severe congenital myasthenic syndrome (CMS) caused by Collagen Q (ColQ) Deficiency.
Product Name : AMP-201
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 30, 2023
Lead Product(s) : AMP-201
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : NIH-NIAMS
Deal Size : Undisclosed
Deal Type : Funding